November 26, 2015
Amgen’s first Humira biosimilar application for ABP 501 to the FDA
Amgen has filed a Biologics License Application (BLA) with the United States (U.S.) Food and Drug Administration (FDA) for ABP 501,…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
November 25, 2015
Glades Drugs recalls its Vitamin D3 capsules
Glades Drugs has voluntarily recalled its Vitamin D3 capsules
November 25, 2015
Allergan settles with New York over Memantine. Agrees to pay $170K for state’s litigation expenses
Allergan has agreed with the New York State Attorney General’s Office to end the litigation under Section 2 of the Sherman Act, and other statutes with the Attorney General over the decision of Forest Laboratories
November 25, 2015
U.S. politicians slam tax-avoiding Pfizer-Allergan deal
U.S. politicians condemned Pfizer Inc’s deal with Allergan Plc as a tax dodge on Monday, bringing another round of hand-wringing in Washington over the corporate tax code, though legislative action before 2017 is unlikely.
November 25, 2015
Allergan and Rugen Therapeutics to jointly support novel therapies Autism Spectrum Disorders
Allergan plc, a company recently bought by Pfizer, and Rugen Therapeutics will jointly support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).
November 25, 2015
Hikma sells ex-Ben Venue factory in Bedford to Xellia
Hikma Pharmaceuticals will sell its manufacturing facilities previously owned by Ben Venue Laboratories based in Bedford, Ohio, to Xellia Pharmaceuticals. In 2014,…
November 25, 2015
Anavex promotes a vice president regulatory affairs
Kristina M. Capiak, CCRP has been promoted the Anavex Life Sciences Corp’s Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, including filings and interactions with the FDA and other regulatory authorities.
November 24, 2015
Presage appoints two new directors
Presage Biosciences, an oncology company has appointed Tachi Yamada and Christoph Lengauer to its board of directors.
November 24, 2015
Lilly’s lung cancer drug in combo with gemcitabine and cisplatin gets FDA’s OK
Eli Lilly has gotten the U.S. Food and Drug Administration (FDA) approval for cancer drug Portrazza, which comes in a form of injection for intravenous use, 800 mg/50 mL, in combination with gemcitabine and cisplatin.
November 24, 2015
Lupin gets a go-ahead to market Blisovi – generic version Warner Chilcott’s Loestrin tablets – in U.S.
US FDA has given Lupin a go to market Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets market generic versions of Warner Chilcott’s Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets.
You must be logged in to post a comment.